An antimetastatic role for decorin in breast cancer

American Journal of Pathology

Volumn 173, Issue 3, 2008, Pages 844-855

  Goldoni, Silvia ^a,b   Seidler, Daniela G ^a,b   Heath, Jack ^a,b   Fassan, Matteo ^a   Baffa, Raffaele ^a   Thakur, Mathew L ^a   Owens, Rick T ^c   McQuillan, David J ^c   Iozzo, Renato V ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LIFECELL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CARCINOMA CELL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ASSAY; TUMOR XENOGRAFT;

EID: 51349167280     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.080275     Document Type: Article

References (54)

1. Iozzo RV: The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 1997, 32:141-174
2. Hocking AM, Shinomura T, McQuillan DJ: Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 1998, 17:1-19
3. Iozzo RV: The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 1999, 274:18843-18846
4. Reed CC, Iozzo RV: The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 2003, 19:249-255
5. Iozzo RV: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998, 67:609-652
6. Tralhão JG, Schaefer L, Micegova M, Evaristo C, Schönherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, Lemarchand P: In vivo selective and distant killing of cancer cells using adenovirusmediated decorin gene transfer. FASEB J 2003, 17:464-466
7. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR: Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Therapy 2004, 11:721-732
8. Schaefer L, Iozzo RV: Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem In press 2008, 238:21305-21309
9. Iozzo RV, Moscatello D, McQuillan DJ, Eichstetter I: Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999, 274:4489-4492
10. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 1995, 92:7016-7020
11. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV: Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 1997, 100:149-157
12. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV: Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Investig 1998, 101:406-412
13. Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnóczky G, Iozzo RV: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 2000, 275:32879-32887
14. Santra M, Reed CC, Iozzo RV: Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping with but distinct from the EGF-binding epitope. J Biol Chem 2002, 277:35671-35681
15. Zhu J-X, Goldoni S, Bix G, Owens RA, McQuillan D, Reed CC, Iozzo RV: Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis. J Biol Chem 2005, 280:32468-32479
16. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-b by the proteoglycan decorin. Nature 1990, 346:281-284
17. Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann P, Gulbins E, Dichgans J, Weller M: Decorin gene transfer-mediated suppression of TGF-b synthesis abrogates experimental malignant glioma growth in vivo. Gene Therapy 1998, 5:1187-1194
18. Ständer M, Naumann U, Wick W, Weller M: Transforming growth factor-b and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 1999, 296:221-227
19. Ferdous Z, Wei VM, Iozzo RV, Höök M, Grande-Allen KJ: Decorin-transforming growth factor-β interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem 2007, 282:35887-35898
20. Guidetti G, Bertoni A, Viola M, Tira E, Balduini C, Torti M: The small proteoglycan decorin supports adhesion and activation of human platelets. Blood 2002, 100:1707-1714
21. Schaefer L, Macakova K, Raslik I, Micegova M, Gröne H-J, Schönherr E, Robenek H, Echtermeyer FG, Grässel S, Bruckner P, Schaefer RM, Iozzo RV, Kresse H: Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002, 160:1181-1191
22. Järveläinen HT, Iruela-Arispe ML, Kinsella MG, Sandell LJ, Sage EH, Wight TN: Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis in vitro. Exp Cell Res 1992, 203:395-401
23. Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage H, Wight TN: A role for decorin in cutaneous wound healing and angiogenesis. Wound Rep Reg 2006, 14:443-452
24. KIP1. J Biol Chem 2001, 276:40687-40692
25. Schönherr E, Sunderkotter C, Schaefer L, Thanos S, Grässel S, Oldberg Å, Iozzo RV, Young MF, Kresse H: Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J Vasc Res 2004, 41:499-508
26. Kinsella MG, Fischer JW, Mason DP, Wight TN: Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem 2000, 275:13924-13932
27. de Lange Davies C, Melder RJ, Munn LL, Mouta-Carreira C, Jain RK, Boucher Y: Decorin inhibits endothelial migration and tube-like structure formation: role of thrombospondin-1. Microvasc Res 2001, 62:26-42
28. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV: Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002, 21:4765-4777
29. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV: Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997, 136:729-743
30. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I: Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 1999, 96:3092-3097
31. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH: Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003, 9:207-214
32. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RA, McQuillan DJ, Iozzo RV: Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 2006, 281:26408-26418
33. Reed CC, Gauldie J, Iozzo RV: Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002, 21:3688-3695
34. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RA, McQuillan DJ, Iozzo RV: Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24:1104-1110
35. Levitzki A, Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267:1782-1788
36. Neri A, Welch D, Kawaguchi T, Nicholson GL: Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst 1982, 68:507-517
37. Ramamurthy P, Hocking AM, McQuillan DJ: Recombinant decorin glycoforms. Purification and structure. J Biol Chem 1996, 271:19578-19584
38. Goldoni S, Owens RT, McQuillan DJ, Shriver Z, Sasisekharan R, Birk DE, Campbell S, Iozzo RV: Biologically active decorin is a monomer in solution. J Biol Chem 2004, 279:6606-6612
39. Chou T-C: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm Rev 2006, 58:621-681
40. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur MT, Barker CA, Camphausen KC, Iozzo RV: Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 2006, 98:1634-1646
41. Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jeffry U, Murray R, McDonald DM: Uniform overexpression and rapid accessibility of a5b1 integrin on blood vessels in tumors. Am J Pathol 2005, 167:193-211
42. Grus WE, Zhang J: Rapid turnover of species-specificity of vomeronasal pheromone receptor genes in mice and rats. Gene 2004, 340:303-312
43. Shi P, Bielawski JP, Yang H, Zhang Y-P: Adaptive diversification of vomeronasal receptor 1 gene in rodents. J Mol Evol 2005, 60:566-576
44. Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL: Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity. J Biol Chem 2000, 275:6987-6995
45. Zhou Y, Brattain MG: Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. Cancer Res 2005, 65:5848-5856
46. Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, Vitali A, Murphy R, Johns TG, Scott AM, Levitzki A, McLachlan G, Webster LK, Burgess AW, Nice EC: Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 2006, 71:1422-1434
47. Zhang W, Chuang YJ, Jin T, Swanson R, Xiong Y, Leung L, Olson ST: Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006, 66:5047-5055
48. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai K-L, Zhang Z-Y, Sahai E, Condeelis J, Segall JE: Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006, 66:192-197
49. Santra M, Eichstetter I, Iozzo RV: An anti-oncogenic role for decorin: down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 2000, 275:35153-35161
50. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: MET, metastasis, motility and more. Nature Rev Mol Cell Biol 2003, 4:915-925
51. Camp RL, Rimm EB, Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86:2259-2265
52. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu J-X, Keene DR, Reed CC, Iozzo RV: A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007, 26:368-381
53. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KLI, Sweeney C: LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007, 27:1934-1946
54. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL: Inhibition of TGF-b with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007, 117:1305-1313